Related Experiment Video
Updated: Jul 2, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective
Valentina Eberlein1,2, Mareike Ahrends2,3, Lea Bayer1
1Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Insights
A novel liposome-formulated, low-energy electron irradiated respiratory syncytial virus (RSV) vaccine shows promise for intranasal delivery. This mucosal vaccine effectively reduces viral load and induces immunity without adverse effects, offering a new strategy against RSV infections.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness in infants and the elderly.
- Current intramuscular vaccines exist, but mucosal vaccines offer enhanced protection against respiratory pathogens.
- Intranasal vaccination strategies are being explored for improved local immune responses.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel liposome-formulated, low-energy electron irradiated RSV (PC-LEEI-RSV) vaccine administered via the intranasal route.
- To assess the immunogenicity and protective potential of PC-LEEI-RSV against RSV challenge in a mouse model.
- To establish a proof-of-principle for using liposome-formulated inactivated viruses for mucosal immunization.
Main Methods:
- Ex vivo safety assessment using precision cut lung slices (PCLSs).
- In vivo immunogenicity and efficacy studies in a mouse model using intranasal prime-boost immunization.
- RSV challenge model to evaluate viral load reduction after vaccination.
Main Results:
- PC-LEEI-RSV demonstrated no adverse effects in PCLSs.
- Intranasal vaccination with PC-LEEI-RSV induced efficient antibody responses in vivo.
- Liposome-formulated LEEI-RSV significantly reduced viral load in mice compared to unformulated LEEI-RSV after challenge.
Conclusions:
- Liposome formulation enhances the efficacy of intranasally administered LEEI-RSV.
- PC-LEEI-RSV is a safe and immunogenic mucosal vaccine candidate for RSV.
- This approach provides a foundation for developing similar mucosal vaccines against other respiratory viruses.
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in the elderly and in children, associated with pediatric hospitalizations. Recently, first vaccines have been approved for people over 60 years of age applied by intramuscular injection. However, a vaccination route via mucosal application holds great potential in the protection against respiratory pathogens like RSV. Mucosal vaccines induce local immune responses, resulting in a fast and efficient elimination of respiratory viruses after natural infection. Therefore, a low-energy electron irradiated RSV (LEEI-RSV) formulated with phosphatidylcholine-liposomes (PC-LEEI-RSV) was tested ex vivo in precision cut lung slices (PCLSs) for adverse effects. The immunogenicity and protective efficacy in vivo were analyzed in an RSV challenge model after intranasal vaccination using a homologous prime-boost immunization regimen. No side effects of PC-LEEI-RSV in PCLS and an efficient antibody induction in vivo could be observed. In contrast to unformulated LEEI-RSV, the mucosal vaccination of mice with PC formulated LEEI-RSV showed a statistically significant reduction in viral load after challenge. These results are a proof-of-principle for the use of LEEI-inactivated viruses formulated with liposomes to be administered intranasally to induce a mucosal immunity that could also be adapted for other respiratory viruses.
